EBV is a ubiquitous herpesvirus that infects approximately 95% of the human population. In most cases, EBV establishes a life-long latent infection in memory B-lymphocytes and does not pose a health risk. Through detection of viral DNA and gene expression, however, EBV has been associated with Burkitt's lymphoma, Hodgkins's lymphoma, lymphoproliferative disorders arising in immunocompromised patrients, and nasopharyngeal carcinoma. Patrients who lack cellular immunity are at particular risk for EBV-assocated diseases. EBV-associated malignancies are unige in that malignant processes correlate with latent rather than acute infection. For this reason, antiviral treatments targeting lytic infection are not effective. Attempts to restore cellular immunity or cytotoxic chemotherapy are the standard treatments. These therapies are not without risk, however, ast the restoration of immunity can cause the loss of grafts in transplant patients and chemotherapy has multiple associated toxicities. Infusion of EBV-specifics, donor cytoxic T-cells have yielded promising result for some patients with post-transplant lymphoproliferative disease, but this therapy remains investigational, expensive, and limited to a few academic centers.
|Effective start/end date||1/27/16 → 1/27/18|
- Eli Lilly and Company (Agmt 01/27/16)